Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells

DC FieldValueLanguage
dc.contributor.authorBélanger, Martin-
dc.contributor.authorGaudreau, Martin-
dc.contributor.authorRoussel, Élise-
dc.contributor.authorCouët, Jacques-
dc.date.accessioned2017-11-14T20:43:33Z-
dc.date.available9999-12-31-
dc.date.issued2004-07-23-
dc.identifier.issn1538-4047fr
dc.identifier.urihttp://hdl.handle.net/20.500.11794/15846-
dc.description.abstractCaveolin 1 expression is downregulated in various cancer cell lines. Interestingly, in several drug-resistant cancer cells, a strong induction of caveolin 1 expression has been reported suggesting a role for caveolin 1 in the acquisition and/or the maintenance of multidrug resistance phenotype. In addition, it was reported that p-glycoprotein localized to caveolin-rich membrane domains in these cells. In this study, we progressively exposed A549 lung adenocarcinoma cells to increasing doses of etoposide. Both R1 and R2 cell lines had greatly increased levels of p-glycoprotein expression while mrp expression levels were moderately increased but only R2 cells had raised caveolin levels compared to control A549 cells. Both caveolin-1 and p-glycoprotein colocalize in Triton-insoluble membrane domains in all our cell lines but only caveolins-1 was solubilized by the addition of octylglucoside at 4C suggesting that these two proteins are located in different membrane domains. Using an anti-caveolin-1 antibody, we did not succeed to immunoprecipitate p-glycoprotein. Interestingly, total cellular cholesterol (the major lipid component of caveolae and triton-insoluble domains) was greatly increased in both R1 and R2 cell lines compared to naive A549 cells.fr
dc.languageengfr
dc.publisherTaylor & Francisfr
dc.subjectcaveolinfr
dc.subjectcaveolaefr
dc.subjectCytotoxic drugsfr
dc.subjectMultidrug resistancefr
dc.titleRole of caveolin-1 in etoposide resistance development in A549 lung cancer cellsfr
dc.typeCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherchefr
dcterms.bibliographicCitationCancer Biology and Therapy, Vol 3 (10), 954-959 (2004)fr
dc.identifier.doi10.4161/cbt.3.10.1112fr
dc.identifier.pubmed15326378fr
dc.subject.rvmCavéolinesfr
dc.subject.rvmCavéolesfr
dc.subject.rvmPoumons -- Cancerfr
dc.subject.rvmCellules cancéreuses -- Résistance aux médicamentsfr
dc.subject.rvmÉtoposidefr
rioxxterms.versionVersion of Recordfr
rioxxterms.version_of_recordhttp://dx.doi.org/10.4161/cbt.3.10.1112fr
rioxxterms.projectMT-14341fr
rioxxterms.project.funder_nameCanadian Institutes of Health Researchfr
bul.rights.periodeEmbargoInfinifr
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
Description SizeFormat 
belanger3-10.pdf
659.45 kBAdobe PDF    Request a copy
All documents in CorpusUL are protected by Copyright Act of Canada.